Drug Development and Approval: A Conversation with the FDA
Real Talk: Eosinophilic Diseases
Release Date: 02/23/2022
The Spoon Theory and Eosinophilic Disorders
Real Talk: Eosinophilic Diseases
Co-host Ryan Piansky, a graduate student and patient advocate living with eosinophilic esophagitis (EoE) and eosinophilic asthma, and co-host Holly Knotowicz, a speech-language pathologist living with EoE, who serves on APFED’s Health Sciences Advisory Council, have a conversation about the Spoon Theory. In this episode, Ryan and Holly discuss the origin of the Spoon Theory, their experiences, and what the Spoon Theory means in their lives. Listen to this episode to learn how the Spoon Theory could work for you. Disclaimer: The information provided in this podcast is designed to...
info_outline
Gastro Girl and GI Diseases: Conversation With Jacqueline Gaulin
Real Talk: Eosinophilic Diseases
Description: Co-host Ryan Piansky, a graduate student and patient advocate living with eosinophilic esophagitis (EoE) and eosinophilic asthma, and co-host Holly Knotowicz, a speech-language pathologist living with EoE, who serves on APFED’s Health Sciences Advisory Council, speak with Jacqueline Gaulin, the Founder of Gastro Girl, a source of information for people living with various gastrointestinal disorders. In this episode, Ryan and Holly interview Jacqueline Gaulin about her career, how she started Gastro Girl, its podcast, and the partnership between Gastro Girl, the American College...
info_outline
The Family Risk of Eosinophilic Gastrointestinal Diseases
Real Talk: Eosinophilic Diseases
Description: Co-host Ryan Piansky, a graduate student and patient advocate living with eosinophilic esophagitis (EoE) and eosinophilic asthma, and co-host Mary Jo Strobel, APFED’s Executive Director, speak with Dr. Kathryn Peterson, MD, MSCI, a Professor of Gastroenterology at the University of Utah Health. In this episode, Ryan and Mary Jo interview Dr. Peterson about the family risk of eosinophilic gastrointestinal diseases, discussing the studies she has done, future work she is planning, and other studies of related topics. She shares that she is a parent to a patient living with an...
info_outline
Remodeling and Eosinophilic Esophagitis (EoE)
Real Talk: Eosinophilic Diseases
Description: Co-host Ryan Piansky, a graduate student and patient advocate living with eosinophilic esophagitis (EoE) and eosinophilic asthma, and co-host Holly Knotowicz, a speech-language pathologist living with EoE, who serves on APFED’s Health Sciences Advisory Council, speak with Dr. Amanda Muir, an Assistant Professor of Pediatrics at the Children’s Hospital of Philadelphia. In this episode, Ryan and Holly interview Dr. Muir about tissue remodeling and eosinophilic esophagitis (EoE). Dr. Muir describes remodeling and stiffening, its effects, and how it relates to treatment and...
info_outline
Journey to an Eosinophilic Esophagitis (EoE) Diagnosis
Real Talk: Eosinophilic Diseases
Description: Co-host Ryan Piansky, a graduate student and patient advocate living with eosinophilic esophagitis (EoE) and eosinophilic asthma, and co-host Holly Knotowicz, a speech-language pathologist living with EoE, who serves on APFED’s Health Sciences Advisory Council, speak with Moises Velasquez-Manoff, a health and science writer living with EoE. He is a contributing writer for the New York Times Magazine. He writes about the human microbiome and its impact on health, as well as climate, COVID-19, and other health and science topics. In this episode, Ryan and Hollyinterview Moises...
info_outline
Community Perspective: Eosinophilic Gastritis (EoG)
Real Talk: Eosinophilic Diseases
Description: Co-host Ryan Piansky, a graduate student and patient advocate living with eosinophilic esophagitis (EoE) and eosinophilic asthma, and co-host Mary Jo Strobel, APFED’s Executive Director, speak with Dr. Jenny Huang, an allergy and immunology fellow at Scripps Clinic, who has a unique perspective of also living with eosinophilic gastritis (EoG). In this episode, Ryan and Mary Jo interview Dr. Jenny Huang about various EGIDs, her allergy and immunology fellowship, her EoG diagnosis, and the elimination diet she follows to treat her EoG. Dr. Huang speaks about patients she sees,...
info_outline
Community Perspective: Eosinophilic Esophagitis
Real Talk: Eosinophilic Diseases
Description: Co-host Ryan Piansky, a graduate student and patient advocate living with eosinophilic esophagitis (EoE) and eosinophilic asthma, and Holly Knotowicz, a speech-language pathologist and feeding specialist living with EoE, who serves on APFED’s Health Sciences Advisory Council, talk with Declan, a teenager living with eosinophilic esophagitis. In this episode, Ryan and Holly interview Declan about his EoE diagnosis, his dietary restrictions, how he receives support from his parents and friends, and upcoming milestones such as transitioning clinical care to an adult provider and...
info_outline
Esophageal String Test: Monitoring Tool Use and Development
Real Talk: Eosinophilic Diseases
Description: Co-host Ryan Piansky, a graduate student and patient advocate living with eosinophilic esophagitis (EoE) and eosinophilic asthma, and Holly Knotowicz, a speech-language pathologist and feeding specialist living with EoE who serves on APFED’s Health Sciences Advisory Council, talk with Drs. Robin Shandas and Steven Ackerman, are scientists who work together at EnteroTrack. In this episode, Ryan and Holly interview Drs. Shandas and Ackerman about the development of the esophageal string test (EST), or simply the string test. They discuss the initial concept and the work that led...
info_outline
Live from APFED’s EOS Connection 2023
Real Talk: Eosinophilic Diseases
Description: Ryan Piansky, a college student and patient advocate living with eosinophilic esophagitis (EoE) and eosinophilic asthma, and Holly Knotowicz, a speech pathologist living with EoE who specializes in feeding therapy and serves on APFED’s Health Sciences Advisory Council recorded this episode live at APFED’s annual patient education conference in Denver, CO. They shared their experiences with this year’s conference, discussed takeaways from the conference presentations, and offered ways to continue the conversation. Recordings of the conference presentations are available to...
info_outline
Proton Pump Inhibitors and EoE
Real Talk: Eosinophilic Diseases
Description: Co-host Mary Jo Strobel, APFED’s Executive Director, is joined by co-host Holly Knotowicz, a speech-language pathologist and feeding specialist living with eosinophilic esophagitis (EoE) who serves on APFED’s Health Sciences Advisory Council. They talk with guest Dr. James Franciosi, Chief of the Division of Gastroenterology, Hepatology, and Nutrition at Nemours Children’s Health in Orlando, Florida. In this episode, Mary Jo Strobel and Holly Knotowicz interview Dr. James Franciosi about his research with proton pump inhibitors, personalized medicine, the different factors...
info_outlineDr. Scott Winiecki is the Director of the Safe Use Initiative at the FDA. He completed his M.D. at the University of Maryland and his pediatric training at the Children’s Hospital of Philadelphia. After 12 years in private pediatric practice, he joined the U.S. Food and Drug Administration in 2011. After working on immune globulin products and vaccines for five years, he joined the Center for Drug Evaluation and Research (CDER) in September 2016. In his current role at the FDA, he is working to reduce preventable harm from medications by collaborating with both public and private groups within the healthcare community.
In this episode, Dr. Winiecki explains the role of the FDA in getting a drug to market. He talks about the different stages a drug has to go through before it reaches the FDA and the phases of clinical trials in assessing a drug’s suitability for public use. Dr. Winiecki gives us an inside look at the intricacies of ensuring the safety and efficacy of a drug, as well as how patients can work with the FDA in terms of drug development. Tune in to find out more.
Disclaimer: The information provided in this podcast is designed to support, not replace the relationship that exists between listeners and their healthcare providers. Opinions, information, and recommendations shared in this podcast are not a substitute for medical advice. Decisions related to medical care should be made with your healthcare provider. Opinions and views of guests and co-hosts are their own.
Key Takeaways:
[1:51] Education partner: Bristol Myers Squibb
[1:54] Mary Jo introduces the guest for this episode, Dr. Scott Winiecki.
[3:14] Dr. Winiecki shares a bit about his background and his role at the FDA.
[3:58] What are some of the steps a drug typically goes through before it reaches the FDA for approval?
[5:04] What are the phases of a clinical trial and what is being assessed in each phase?
[8:01] How does the process differ if the drug is for rare diseases, or if the drug is already approved for some other use case, or approved in other countries?
[9:15] How does the FDA engage with patients that are enrolled in a clinical trial?
[9:45] What protections are in place for people participating in a clinical trial?
[10:46] One concern patients may have in deciding whether to participate in a clinical trial involving investigational drugs is whether they will be able to access that medicine after the trial ends. Dr. Winiecki explains how decisions are made regarding post-trial access to a drug.
[11:50] The FDA has a variety of different designations it gives to drugs. What does each of these designations mean?
[16:55] What are some circumstances that might cause a delay in the approval process?
[17:56] On average, how long is the development timeline for a drug to come to market?
[18:25] Who decides which disorder a drug will be approved for?
[20:20] How does it determine if a medicine would be made available over the counter or by prescription?
[20:58] What is the FDA involvement after a drug is approved?
[22:27] How would patients report side effects that they believe might be caused by a drug?
[23:19] What are some considerations in the labeling of allergens used as inactive ingredients in drugs?
[24:10] What is the role that patients play in drug development? What is the value of having the patient and families engaged and involved?
[26:41] What are some ways patients and families can engage with the FDA, apart from the PFDD meetings?
[27:40] What are some FDA programs that might focus on rare disease?
[29:23] For more information and resources, visit the FDA website.
Mentioned in This Episode:
American Partnership for Eosinophilic Disorders (APFED)
APFED on YouTube, Twitter, Facebook, Pinterest, Instagram
Call FDA — 1-888-INFO-FDA (1-888-463-6332)
Clinical trials for eosinophil-associated diseases
EOS Connections Online Community
This episode is brought to you thanks to the support of our Education Partner Bristol Myers Squibb.
Tweetables:
“Pre-clinical research can answer basic questions about drug safety, but they’re not a substitute for ways the drug can interact in the human body.” — Dr. Winiecki
“The FDA continues to look at benefits and risks of a therapy throughout its lifecycle even after a drug is approved.” — Dr. Winiecki
“It’s also noteworthy that most rare diseases do not have any FDA approved treatments.” — Dr. Winiecki
“The FDA has a really important role in protecting patients enrolled in clinical trials.” — Dr. Winiecki
“The FDA estimates it takes about 8.5 years to study and test a new drug before it can be approved for the general public.” — Dr. Winiecki
“Patient involvement is very important and perhaps even more important in the context of rare diseases because obviously, no one knows the disease as well as the patient and what sort of outcomes or benefits would be important.” — Dr. Winiecki